Medindia

X

Swiss Drug Firm Collaborates With Amgen to Develop Treatments for Alzheimer's Disease

by Reshma Anand on  September 5, 2015 at 1:02 PM Corporate News   - G J E 4
Novartis partners with the California-based biotech company Amgen to develop and sell neuroscience treatments for illnesses and ailments like Alzheimer's disease and migraine headaches.
Swiss Drug Firm Collaborates With Amgen to Develop Treatments for Alzheimer's Disease
Swiss Drug Firm Collaborates With Amgen to Develop Treatments for Alzheimer's Disease
Advertisement

Novartis stated, "Amgen will make initial payments and cover some research and development costs at the start with regard to the BACE inhibitor program for treatment of Alzheimer's. That will be followed by a 50-50 cost and profit sharing arrangement."

Advertisement
As for migraine, Novartis will fund some R&D expenses for an agreed period and pay Amgen double-digit royalties on sales. The Basel-based company will also receive some commercialization and co-development rights to "the investigative molecules in Amgen's migraine portfolio."

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All